MXPA03009681A - METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA. - Google Patents

METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA.

Info

Publication number
MXPA03009681A
MXPA03009681A MXPA03009681A MXPA03009681A MXPA03009681A MX PA03009681 A MXPA03009681 A MX PA03009681A MX PA03009681 A MXPA03009681 A MX PA03009681A MX PA03009681 A MXPA03009681 A MX PA03009681A MX PA03009681 A MXPA03009681 A MX PA03009681A
Authority
MX
Mexico
Prior art keywords
tegafur
cyclophosphamide
uracil
administration
folinic acid
Prior art date
Application number
MXPA03009681A
Other languages
English (en)
Inventor
Jody Ressler-Tatro
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03009681A publication Critical patent/MXPA03009681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA03009681A 2001-04-26 2002-04-22 METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA. MXPA03009681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28672901P 2001-04-26 2001-04-26
PCT/US2002/012769 WO2002087335A1 (en) 2001-04-26 2002-04-22 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide

Publications (1)

Publication Number Publication Date
MXPA03009681A true MXPA03009681A (es) 2004-02-12

Family

ID=23099905

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009681A MXPA03009681A (es) 2001-04-26 2002-04-22 METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA.

Country Status (10)

Country Link
US (1) US6620816B2 (es)
EP (1) EP1399021A1 (es)
JP (1) JP2004533434A (es)
CA (1) CA2445262A1 (es)
CZ (1) CZ20032835A3 (es)
HU (1) HUP0303953A3 (es)
MX (1) MXPA03009681A (es)
NO (1) NO20034690D0 (es)
PL (1) PL373247A1 (es)
WO (1) WO2002087335A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4596220B2 (ja) 2001-06-26 2010-12-08 ソニー株式会社 画像処理装置および方法、記録媒体、並びにプログラム
DE60233569D1 (de) * 2001-06-26 2009-10-15 Sony Corp Mputerprogramm zur bildverarbeitung, sowie bilderfassungsvorrichtung
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
JP2006160664A (ja) * 2004-12-07 2006-06-22 Vitamin C60 Bioresearch Kk フリーラジカル疾患予防治療用組成物
WO2008106721A1 (en) * 2007-03-02 2008-09-12 University Of Wollongong Compositions and methods for delivery of anti-cancer agents
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) * 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells

Also Published As

Publication number Publication date
US6620816B2 (en) 2003-09-16
US20020187956A1 (en) 2002-12-12
NO20034690L (no) 2003-10-20
WO2002087335A1 (en) 2002-11-07
CZ20032835A3 (cs) 2007-06-20
EP1399021A1 (en) 2004-03-24
CA2445262A1 (en) 2002-11-07
HUP0303953A2 (hu) 2004-04-28
PL373247A1 (en) 2005-08-22
HUP0303953A3 (en) 2005-05-30
JP2004533434A (ja) 2004-11-04
NO20034690D0 (no) 2003-10-20

Similar Documents

Publication Publication Date Title
WO1999054326A8 (de) Dihydropyrimidine
ZA200306541B (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin.
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
MXPA03010020A (es) PROCEDIMIETO PARA LA PREPARACIoN DE UREA.
HK1083503A1 (en) Novel pyrimidine-4, 6-dicarboxamides for the selective inhibition of collagenases
EP1416052A4 (en) PROCESS FOR THE PRODUCTION OF 1,4-DIHYDROXY-2-NAPHTHOTIC ACID
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
MXPA03009527A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE INDENOS 1,3-SUSTITUIDOS Y COMPUESTOS AZAPOLICICLICOS CONDENSADOS CON ARILO.
HK1053839A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.
IL157874A0 (en) The citrate salt of 5,8,14,-triazatetracyclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
HK1068329A1 (en) Process for the preparation of 2,6-naphthalenedicarboxylic acid
ZA995597B (en) Process for the preparation of nicotinic acid.
MXPA03001484A (es) Quinazolinas, medicamentos que contienen estos compuestos, y son efectivos como inhbidores de tirosina quinasa, su utilizacion y metodos para su produccion.
MXPA03009681A (es) METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA.
AP2004003070A0 (en) The method of treating cancer.
PL373723A1 (en) Process for the preparation of 1,2-benzisoxazole-3-acetic acid
AU2001240001A1 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
ZA200208346B (en) Polyamide nucleic acid derivatives, agents and methods for producing the same.
EP1613606A4 (en) PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES
MXPA03008119A (es) Metodo para la produccion de 2,6-dialquilmorfolinas n-sustituidas.
MXPA03006534A (es) Metodo para obtener (3-ciano-1h-indol-7-il)-(4(4- fluorfenetil)-piperazin-1-il)-metanona y sus sales.
ZA200303236B (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.